An evolution from pilot to a commercial contract should be a given, based on the efficacy of the product and the relationships at director level between the two companies. A 23.5% increase post-announcement suggests this was surprisingly not baked into the SP.
I place far more weight on the revenue figure in the next 4C that represents the value of the technology to Integral and others in real commercial terms. 4Dmedical has a contract with Imed that is a bigger player than Integral. This should be generating $$$. A contract is not revenue.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $118.7M | |||
| Open | High | Low | Value | Volume |
| 25.5¢ | 26.0¢ | 25.0¢ | $103.4K | 403.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 260900 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 49495 | 3 |
View Market Depth
| Last trade - 11.40am 25/06/2025 (20 minute delay) ? |
| 4DX (ASX) Chart |